Analyst Price Target is $26.00
▲ +715.05% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for BioLineRx in the last 3 months. The average price target is $26.00, with a high forecast of $26.00 and a low forecast of $26.00. The average price target represents a 715.05% upside from the last price of $3.19.
Current Consensus is
Moderate Buy
The current consensus among 2 contributing investment analysts is to moderate buy stock in BioLineRx. This rating has held steady since March 2025, when it changed from a Buy consensus rating.
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Read More